[go: up one dir, main page]

WO2014062228A8 - Système d'administration de médicament à base d'un nanovecteur amélioré pour surmonter la résistance à un médicament - Google Patents

Système d'administration de médicament à base d'un nanovecteur amélioré pour surmonter la résistance à un médicament Download PDF

Info

Publication number
WO2014062228A8
WO2014062228A8 PCT/US2013/032502 US2013032502W WO2014062228A8 WO 2014062228 A8 WO2014062228 A8 WO 2014062228A8 US 2013032502 W US2013032502 W US 2013032502W WO 2014062228 A8 WO2014062228 A8 WO 2014062228A8
Authority
WO
WIPO (PCT)
Prior art keywords
tumor cells
nanovectors
therapeutic compositions
targeting
nanovector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/032502
Other languages
English (en)
Other versions
WO2014062228A1 (fr
Inventor
David S. BASKIN
Daniela MARCANO
Martyn A. Sharpe
James M. Tour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William Marsh Rice University
Methodist Hospital
Methodist Hospital Research Institute
Original Assignee
William Marsh Rice University
Methodist Hospital
Methodist Hospital Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Marsh Rice University, Methodist Hospital, Methodist Hospital Research Institute filed Critical William Marsh Rice University
Priority to CA2912975A priority Critical patent/CA2912975A1/fr
Priority to JP2015537686A priority patent/JP2015536319A/ja
Priority to US14/436,127 priority patent/US20150216975A1/en
Publication of WO2014062228A1 publication Critical patent/WO2014062228A1/fr
Anticipated expiration legal-status Critical
Publication of WO2014062228A8 publication Critical patent/WO2014062228A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Divers modes de réalisation de la présente invention concernent des compositions thérapeutiques pour le ciblage spécifique de cellules tumorales. Dans certains modes de réalisation, les compositions thérapeutiques comprennent en général : (1) une pluralité de nanovecteurs; (2) un ou plusieurs principes actifs associés aux nanovecteurs, le ou les principes actifs ayant une activité dirigée contre les cellules tumorales; (3) un ou plusieurs activateurs de principe actif associés aux nanovecteurs; et (4) un ou plusieurs agents de ciblage associés aux nanovecteurs, le ou les agents de ciblage ayant une activité de reconnaissance pour un ou plusieurs marqueurs des cellules tumorales. Des modes de réalisation supplémentaires de la présente invention concernent des procédés de ciblage de cellules tumorales chez un sujet par l'administration d'une ou plusieurs des compositions thérapeutiques susmentionnées au sujet. Des modes de réalisation supplémentaires de la présente invention concernent des procédés de formulation des compositions thérapeutiques susmentionnées pour le ciblage de cellules tumorales chez un sujet d'une manière personnalisée.
PCT/US2013/032502 2007-10-03 2013-03-15 Système d'administration de médicament à base d'un nanovecteur amélioré pour surmonter la résistance à un médicament Ceased WO2014062228A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2912975A CA2912975A1 (fr) 2012-10-16 2013-03-15 Systeme d'administration de medicament a base d'un nanovecteur ameliore pour surmonter la resistance a un medicament
JP2015537686A JP2015536319A (ja) 2012-10-16 2013-03-15 薬剤耐性を克服するための改善されたナノベクターベースの薬物送達システム
US14/436,127 US20150216975A1 (en) 2007-10-03 2013-03-15 Nanovector based drug delivery system for overcoming drug resistance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261714478P 2012-10-16 2012-10-16
US61/714,478 2012-10-16

Publications (2)

Publication Number Publication Date
WO2014062228A1 WO2014062228A1 (fr) 2014-04-24
WO2014062228A8 true WO2014062228A8 (fr) 2015-06-11

Family

ID=50488627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/032502 Ceased WO2014062228A1 (fr) 2007-10-03 2013-03-15 Système d'administration de médicament à base d'un nanovecteur amélioré pour surmonter la résistance à un médicament

Country Status (3)

Country Link
JP (1) JP2015536319A (fr)
CA (1) CA2912975A1 (fr)
WO (1) WO2014062228A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776029T3 (es) 2012-10-08 2020-07-28 St Jude Childrens Res Hospital Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina
RU2771104C2 (ru) 2014-05-14 2022-04-26 Таргиммьюн Терапьютикс Аг Улучшенные полиэтилениминовые полиэтиленгликолевые векторы
WO2016098562A1 (fr) * 2014-12-19 2016-06-23 グリコ栄養食品株式会社 COMPOSITION SOLUBILISANTE OU DISPERSANTE POUR SUBSTANCES PEU SOLUBLES OU INSOLUBLES COMPORTANT UN SYSTÈME π-CONJUGUÉ
EP3615077A1 (fr) 2017-04-28 2020-03-04 William Marsh Rice University Traitements de dysfonctionnements aigus et chroniques de la chaîne de transport d'électrons mitochondriaux et matériaux graphéniques destinés à leur utilisation
CN108017623A (zh) * 2017-12-06 2018-05-11 石家庄学院 一种聚乙二醇三氮唑白杨素衍生物及其制备方法和应用
CN115317621B (zh) * 2022-05-16 2025-07-25 华东理工大学 一氧化碳和铁螯合剂靶向联合可控给药纳米复合药物体系及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
TW200307563A (en) * 2002-02-14 2003-12-16 Sixty Inc C Use of BUCKYSOME or carbon nanotube for drug delivery
WO2004087094A2 (fr) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Compositions pour traiter la resistance aux medicaments
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
JP2010500375A (ja) * 2006-08-08 2010-01-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 活性剤の多段階送達
WO2009070380A2 (fr) * 2007-10-03 2009-06-04 William Marsh Rice University Compositions de nanotubes de carbone solubles dans l'eau pour l'administration d'un médicament et applications médicales
US8916606B2 (en) * 2009-10-27 2014-12-23 William Marsh Rice University Therapeutic compositions and methods for targeted delivery of active agents

Also Published As

Publication number Publication date
JP2015536319A (ja) 2015-12-21
CA2912975A1 (fr) 2014-04-24
WO2014062228A1 (fr) 2014-04-24

Similar Documents

Publication Publication Date Title
EP4600271A3 (fr) Conjugué de molécule bioactive, son procédé de préparation et son utilisation
WO2011133925A3 (fr) Administration cytosolique photoactivée et ciblée de médicament
WO2013067199A3 (fr) Administration sous-cutanée de conjugués polymères d'agents thérapeutiques
WO2012103038A3 (fr) Compositions de nanoparticules, leurs formulations et leurs utilisations
WO2014062228A8 (fr) Système d'administration de médicament à base d'un nanovecteur amélioré pour surmonter la résistance à un médicament
SG10201806917PA (en) Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
WO2015023649A3 (fr) Peptides destinés à améliorer l'administration transdermique
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
PH12014500386A1 (en) Combination treatment for hepatitis c
TN2014000345A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
WO2011087548A3 (fr) Compositions thérapeutiques et méthodes d'administration ciblée de principes actifs
HK1200695A1 (en) Optimised subcutaneous therapeutic agents
WO2013052158A3 (fr) Nanovecteurs ciblés et leur utilisation pour le traitement de tumeurs cérébrales
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp
ZA202207211B (en) Peptide docking vehicle for targeted nucleic acid delivery
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
WO2013112525A3 (fr) Évènement pdab4468.18.07.1de coton résistant aux herbicides
WO2012040331A3 (fr) Nanoparticules multicouches
MX364934B (es) Agente para prevenir y/o tratar dolor neuropático periférico causado por fármaco contra el cáncer.
BR112014007177A2 (pt) agente antifúngico
IN2014DN10134A (fr)
TOGNINI Gender Diversity in the Management Consulting Industry
何力 A Study on Judith Butler's Social Gender
Ratcliff et al. Team Pride influences Proactive Behavioral Support for Sports Teams
郑志阳 My Good Friend and I

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13847700

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase in:

Ref document number: 2015537686

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14436127

Country of ref document: US

ENP Entry into the national phase in:

Ref document number: 2912975

Country of ref document: CA

122 Ep: pct application non-entry in european phase

Ref document number: 13847700

Country of ref document: EP

Kind code of ref document: A1